MedTrace Logo

Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers

NCT07231861 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-11-19

No results posted yet for this study

Summary

To Evaluate the Safety and Pharmacokinetics of Pranlukast hydrate in Healthy Adults.

Conditions

  • Bronchial Asthma
  • Perennial Allergic Rhinitis

Interventions

DRUG

AJU-R713

Oral formulation

DRUG

R713R

Oral formulation

Sponsors & Collaborators

  • AJU Pharm Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-31
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07231861 on ClinicalTrials.gov